Biosearch Announces Acquisition of European Companies DNA Technology and VitraBio
News Jul 23, 2013
Biosearch Technologies, Inc. (Biosearch) has announced that it has acquired the oligonucleotide manufacturing division of the Danish company DNA Technology A/S (DNA Technology) and German CPG manufacturer VitraBio GmbH (VitraBio).
With the acquisition of DNA Technology, Biosearch has added a highly skilled production team with a mature quality system and an established European customer base focused in the Nordic countries.
DNA Technology specializes in production of modified oligos, and will benefit from full access to the breadth of specialty modifications produced by Biosearch.
In addition, Biosearch will provide manufacturing tools and access to its substantial IP portfolio enabling DNA Technology to expand production capabilities and product offerings in order to better serve an expanding customer base.
With the acquisition of German controlled-pore glass (CPG) manufacturer VitraBio in September 2011, Biosearch gains control over VitraBio’s sophisticated CPG manufacturing technology and unique production facility, which expands its already extensive repertoire of oligo synthesis tools and processes.
In addition to continuing production of DNA/RNA synthesis supports for the research and therapeutic oligo markets, Biosearch intends to bring chemical manufacturing capabilities to VitraBio’s Steinach facility to supplement existing US production of specialty amidites and modified CPGs.
The acquisition of DNA Technology and VitraBio marks Biosearch’s increasing commitment to support European biotechnology and diagnostic markets.
Furthermore, Biosearch has secured important manufacturing redundancy for its North American operations as well as a strong base from which to grow sales, production and regulated contract manufacturing capabilities throughout Europe.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019